Company: RPTX
Filing Date: 2025-11-20
Form Type: DEFA14A
Source: 0001193125-25-290058
Chunk: 0

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-20
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material Pursuant to §240.14a-12 |

Repare Therapeutics Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No feerequired. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11 |

Repare Therapeutics Enters into Support and Voting Agreements with Significant

Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) – November20, 2025 –Repare Therapeutics Inc. (“Repare” or
the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into of a definitive arrangement agreement with XenoTherapeutics, Inc.
and Xeno Acquisition Corp. (jointly, “Xeno”), a non-profit biotechnology company, pursuant to which Xeno will acquire (the “Transaction”) all of the issued and outstanding common shares
of Repare (the “Common Shares”), certain entities affiliated with Biotechnology Value Fund, L.P., Blue Owl Capital Holdings LP, and certain entities affiliated with OrbiMed have each entered into a support and voting agreement
pursuant to which they have agreed to vote their Common Shares in favor of the special resolution approving the Transaction.

Considering the previously
announced support and voting agreements entered into by the directors and executive